Health Care Expenditure Expected to Top GDP Growth 2024 to 2033
By Elana Gotkine HealthDay Reporter
Medically reviewed by Drugs.com

THURSDAY, July 3, 2025 -- The annual growth in national health spending is expected to be faster than average gross domestic product (GDP) growth during 2024 to 2033, according to a study published online June 25 in Health Affairs.
Sean P. Keehan, from the U.S. Centers for Medicare & Medicaid Services in Baltimore, and colleagues projected national health expenditures for 2024 to 2033.
The authors note that national health expenditures are projected to have increased 8.2 and 7.1 percent in 2024 and 2025, respectively, reflecting continued strong growth in health care services and goods use. Health spending growth is expected to average 5.6 percent during 2026 to 2027, partly due to a decline in the share of the population with health insurance (relating to expiration of the temporary enhanced Marketplace premium tax credits in the 2022 Inflation Reduction Act) and partly due to an anticipated slowdown in utilization growth. For the full 2024 to 2033 projection period, national health care expenditure growth is expected to outpace that of the GDP each year (averaging 5.8 percent versus 4.3 percent), resulting in a health share of GDP that reaches 20.3 percent by 2033, an increase from 17.6 percent in 2023.
"Although the projections presented here reflect current law, future legislative and regulatory health policy changes could have a significant impact on the projections of health insurance coverage, health spending trends, and related cost-sharing requirements, and they thus could ultimately affect the health share of GDP by 2033," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-07-04 12:00
Read more

- Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
- Bans on Flavored Vapes Have Pros And Cons, Study Finds
- Patients With Diabetes More Likely to Experience Adverse Financial Outcomes
- High Dietary Inflammatory Index Tied to Increased Prevalence of Eczema
- Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
- Insomniacs With Inflammation Prone To Depression
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions